Back to top

BioMarin price target raised to $124 from $119 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BioMarin (BMRN) to $124 from $119 and keeps an Overweight rating on the shares. Published first on...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)